First quarter: a record result and awards to employees

Breaking through 3 million euro in turnover, ASA marks an excellent result for the first 3 months of activity of 2021 thanks to a significant increase in the sales of its therapies for the human and veterinary sector worldwide.

The performance is the result of the strategy developed and applied consistently throughout 2020, during which the company, despite having drastically reduced its production activity during certain moments of the year without in any case ever suspending it, continued to invest in training and in the implementation of its own sales and after-sales network. This intervention plan allowed closing the annus horribilis in the black, thanks also to wise choices in managing resources (layoffs for short periods and with diversified methods by department, smart working, etc.).

Despite the complexity of the economic period, ASA has also decided to allocate a greater amount than ever distributed in previous years towards the partial relief of the contraction in remuneration caused by the COVID-19 redundancy fund and to distribute additional bonuses linked to sales results as well as to the number of webinars and online training sessions held in 2020. The latter activities contributed to starting 2021 with a double-digit percentage growth, as confirmed by the excellent Asian performances, South Korea in the lead, and by the European ones (France and England in first place).
The response of the Italian market has also been meaningful: + 15% on the target budget for the first quarter of 2021 for sales of rehabilitation and physiotherapy devices in the human and vet fields.

“We have ended a difficult 2020 by investing and presenting new Therapeutic Solutions, now we are looking to the near future with great attention, aware that there is a great deal to develop in order to create a recovery that is solid, structured and continuous" comments Roberto Marchesini, ASA’s General Manager.